Treatment challenges in axial spondylarthritis and future directions (Q38124281)

29 August 2017

Treatment challenges in axial spondylarthritis and future directions (English)

1 reference

29 August 2017

Joachim Sieper

1

1 reference

29 August 2017

1 September 2013

1 reference

Current Rheumatology Reports

29 August 2017

1 reference

29 August 2017

15

1 reference

29 August 2017

9

1 reference

29 August 2017

356

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-013-0356-9

29 August 2017

0 references

cites work

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-013-0356-9

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

21 January 2018

1 reference

12 December 2020

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

1 reference

12 December 2020

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

12 December 2020

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

1 reference

12 December 2020

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry

1 reference

12 December 2020

Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

12 December 2020

Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation

1 reference

12 December 2020

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease

1 reference

12 December 2020

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two

1 reference

12 December 2020

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

1 reference

12 December 2020

Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.

1 reference

12 December 2020

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

1 reference

12 December 2020

ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis

1 reference

12 December 2020

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.

1 reference

12 December 2020

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis

1 reference

12 December 2020

10.1007/S11926-013-0356-9

Identifiers

DOI

1 reference

PubMed ID

23888365

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23888365